Abstract
Summary
The global peptide synthesis market size is projected to reach USD 859 million by 2028 from 601 million in 2023, at a CAGR of 7.4 % during the forecast period. Factors such advancement in the field of peptide synthesis, and increased demand for reagents used in peptide synthesis is expected to experience steady growth leading to positive impact on the growth of peptide synthesis products & services.
“The reagents segment accounted for the highest growth rate in the peptide synthesis market, by product & service, during the forecast period”
In 2022, the reagents segment accounted for the highest growth rate. The peptide synthesis reagents market is further segmented into resins, amino acids, coupling reagents, dyes and fluorescent labeling reagents, and other reagents (such as protecting reagents, linkers, buffers, solvents, and solutions). The requirement of reagents in bulk quantities, expanding applications of peptides in therapeutics, drug design, and gene synthesis are some of the factors anticipated to project the growth of the segment.
“Asia Pacific region is likely to grow at a faster pace.”
The peptide synthesis market is divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the dominant share of the peptide synthesis market. The dominance of the region is attributable to various factors such as the presence of leading players in the region coupled with the ongoing research activities of developing new targeted therapies. Asia Pacific region is likely to grow at a faster pace owing to various factors such as the growing awareness of personalized therapeutics, rising government initiatives for generic medicines in the region, and the emergence of new market players in the peptide synthesis market.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70%, and Demand Side - 30%
• By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
Lists of Companies Profiled in the Report:
• Bachem Holding AG (Switzerland)
• Thermo Fisher Scientific, Inc. (US)
• Merck KGaA (Germany)
• GenScript Biotech Corporation (China)
• Kaneka Corporation (Japan)
• Biotage AB (Sweden)
• Syngene International Ltd. (India)
• Mesa Laboratories Inc. (US)
• CEM Corporation (US)
• ProteoGenix (France)
• Bio-Synthesis Inc. (US)
• Dalton Pharma Services (Canada)
• AAPPTec (US)
• vivitide (US)
• AnyGen Co., Ltd. (South Korea)
• CSBio (US)
• Advanced Chemtech (US)
• Luxembourg Bio Technologies Ltd. (Israel)
• JPT Peptide Technologies GmbH (Germany)
• AmbioPharm Inc. (US)
• Aurigene Pharmaceutical Services Ltd. (India)
• Corden Pharma International (Germany)
• ChemPep Inc. (US)
• CPC Scientific Inc. (US)
• Purolite Pvt Ltd. (US)
Research Coverage:
This report provides a detailed picture of the peptide synthesis market. It aims at estimating the size and future growth potential of the market across different segments, such the product, application, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall peptide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (the increasing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced automated peptide synthesizers), restraints (Lack of a unified set of regulations for therapeutic peptides, High cost of instruments), opportunities (Emerging markets in the Asia Pacific region, Development of personalized medicines), and challenges (Issues associated with the route of administration of peptide drugs, Addressing environmental impact of chemical synthesis of peptides.)
• Product & Service Development/Innovation: Detailed insights on newly launched products, and technological assessment of the peptide synthesis market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the peptide synthesis market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the peptide synthesis market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product & service offerings of leading players like GenScript Biotech Corporation (China), Thermo Fisher Scientific, Inc. (US), Bachem Holding AG (Switzerland), Kaneka Corporation (US), Inc.and Merck KGaA (Germany) and among others in the peptide synthesis market.
Table of Contents
1 INTRODUCTION 34
1.1 STUDY OBJECTIVES 34
1.2 MARKET DEFINITION 34
1.2.1 INCLUSIONS & EXCLUSIONS 34
1.3 MARKET SCOPE 35
1.3.1 MARKETS COVERED 35
1.3.2 YEARS CONSIDERED 35
1.4 CURRENCY CONSIDERED 36
1.5 LIMITATIONS 36
1.6 STAKEHOLDERS 36
1.7 SUMMARY OF CHANGES 37
1.7.1 RECESSION IMPACT 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH DATA 38
2.1.1 SECONDARY DATA 39
2.1.2 PRIMARY DATA 40
2.2 MARKET SIZE ESTIMATION 41
2.2.1 INSIGHTS FROM PRIMARIES 44
2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, APPLICATION, AND END USER) 44
2.3 GROWTH RATE ASSUMPTIONS 45
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 47
2.5 STUDY ASSUMPTIONS 48
2.6 RISK ANALYSIS 48
2.7 IMPACT OF ECONOMIC RECESSION ON PEPTIDE SYNTHESIS MARKET 48
3 EXECUTIVE SUMMARY 50
4 PREMIUM INSIGHTS 53
4.1 PEPTIDE SYNTHESIS MARKET OVERVIEW 53
4.2 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2022) 54
4.3 PEPTIDE SYNTHESIS MARKET SHARE, BY TECHNOLOGY (2022) 54
4.4 PEPTIDE SYNTHESIS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 55
4.5 PEPTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS 57
5.2.1 DRIVERS 58
- 5.2.1.1 Increasing use of peptides in pharmaceutical drugs 58
- 5.2.1.2 Increase in research activities and availability of funding for R&D 61
- 5.2.1.3 Development of advanced automated peptide synthesizers 62
5.2.2 RESTRAINTS 63
- 5.2.2.1 Lack of unified set of regulations for therapeutic peptides 63
- 5.2.2.2 High cost of instruments 63
5.2.3 OPPORTUNITIES 64
- 5.2.3.1 Emerging markets in Asia Pacific region 64
- 5.2.3.2 Development of personalized medicines 64
5.2.4 CHALLENGES 65
- 5.2.4.1 Issues associated with route of administration of peptide drugs 65
- 5.2.4.2 Addressing environmental impact of chemical synthesis of peptides 65
5.3 RANGES/SCENARIOS 66
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 67
5.5 VALUE CHAIN ANALYSIS 67
5.6 TECHNOLOGY ANALYSIS 68
5.7 PATENT ANALYSIS 69
5.8 ECOSYSTEM ANALYSIS OF PEPTIDE SYNTHESIS MARKET 72
5.9 PORTER’S FIVE FORCES ANALYSIS 74
5.9.1 THREAT OF NEW ENTRANTS 74
5.9.2 THREAT OF SUBSTITUTES 74
5.9.3 BARGAINING POWER OF SUPPLIERS 74
5.9.4 BARGAINING POWER OF BUYERS 75
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 75
5.10 REGULATORY ANALYSIS 75
5.10.1 REGULATIONS FOR PEPTIDE-BASED DRUGS 75
5.10.2 REGULATIONS FOR PEPTIDE SYNTHESIS PRODUCTS 75
5.10.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76
5.11 KEY CONFERENCES AND EVENTS IN 2023 79
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 79
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 79
5.12.2 BUYING CRITERIA 80
6 PEPTIDE SYNTHESIS MARKET, BY PRODUCT & SERVICE 81
6.1 INTRODUCTION 82
6.2 REAGENTS 82
6.2.1 RESINS 85
- 6.2.1.1 Increasing adoption of solid-phase peptide synthesis technology to boost market 85
6.2.2 AMINO ACIDS 87
- 6.2.2.1 Amino acids play crucial role in synthesis of peptides 87
6.2.3 COUPLING REAGENTS 89
- 6.2.3.1 Vital role of coupling reagents in peptide bond formation to boost market 89
6.2.4 DYES & FLUORESCENT LABELING REAGENTS 92
- 6.2.4.1 Fluorescent labeling reagents play crucial role in understanding success rate of peptide synthesis reactions 92
6.2.5 OTHER REAGENTS 95
6.3 EQUIPMENT 97
6.3.1 PEPTIDE SYNTHESIZERS 100
- 6.3.1.1 Rising automation in peptide synthesizers to drive market growth 100
6.3.2 CHROMATOGRAPHY EQUIPMENT 103
- 6.3.2.1 Reverse-phase HPLC used for purification of synthetic peptides to promote market growth 103
6.3.3 LYOPHILIZERS 106
- 6.3.3.1 Lyophilization to enable longer shelf life and easy transportation of peptides 106
6.4 SERVICES 108
6.4.1 RISE IN RESEARCH ACTIVITIES IN PROTEOMICS, GENOMICS, AND PEPTIDE THERAPEUTICS TO DRIVE MARKET 108
7 PEPTIDE SYNTHESIS MARKET, BY TECHNOLOGY 111
7.1 INTRODUCTION 112
7.2 SOLID-PHASE PEPTIDE SYNTHESIS 112
7.2.1 EASE OF USE OF SOLID-PHASE PEPTIDE SYNTHESIS TECHNOLOGY TO DRIVE GROWTH 112
7.3 SOLUTION-PHASE PEPTIDE SYNTHESIS 115
7.3.1 ABILITY TO PRODUCE LARGE QUANTITIES OF HIGH-QUALITY PEPTIDES COST-EFFECTIVELY TO DRIVE GROWTH 115
7.4 HYBRID & RECOMBINANT TECHNOLOGY 118
7.4.1 PRODUCTION OF PEPTIDES WITH HIGH COMPLEXITY TO BOOST MARKET 118
8 PEPTIDE SYNTHESIS MARKET, BY END USER 122
8.1 INTRODUCTION 123
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 123
8.2.1 USE OF PEPTIDES IN DRUG DEVELOPMENT APPLICATIONS TO DRIVE GROWTH 123
8.3 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS AND CONTRACT RESEARCH ORGANIZATIONS (CDMOS AND CROS) 126
8.3.1 INCREASING DEMAND FOR COST-EFFECTIVE PEPTIDE SYNTHESIS SERVICES TO DRIVE GROWTH 126
8.4 ACADEMIC & RESEARCH INSTITUTES 129
8.4.1 INCREASE IN FINANCIAL AND REGULATORY SUPPORT FOR RESEARCH TO BOOST MARKET GROWTH 129
9 PEPTIDE SYNTHESIS MARKET, BY REGION 133
9.1 INTRODUCTION 134
9.2 NORTH AMERICA 134
9.2.1 US 138
- 9.2.1.1 US to dominate North American peptide synthesis market during forecast period 138
9.2.2 CANADA 140
- 9.2.2.1 Availability of research funding in Canada to drive market growth 140
9.3 EUROPE 142
9.3.1 GERMANY 145
- 9.3.1.1 Government initiatives and rise in funding for peptide synthesis to propel growth 145
9.3.2 UK 148
- 9.3.2.1 Growth in life science research to drive market growth 148
9.3.3 FRANCE 150
- 9.3.3.1 Government funding for proteomics and genomics research to propel market growth 150
9.3.4 ITALY 152
- 9.3.4.1 Increase in life science research to boost market growth in Italy 152
9.3.5 SPAIN 155
- 9.3.5.1 Rising focus on research and innovation to support market growth 155
9.3.6 REST OF EUROPE 157
9.4 ASIA PACIFIC 160
9.4.1 CHINA 164
- 9.4.1.1 China to register highest growth rate due to increase in investments in R&D 164
9.4.2 JAPAN 167
- 9.4.2.1 Rise in collaborations between companies in Japan to propel market growth 167
9.4.3 INDIA 169
- 9.4.3.1 Government support for scientific research to drive market growth 169
9.4.4 SOUTH KOREA 171
- 9.4.4.1 Growing research efforts in biopharmaceutical sector to boost market growth 171
9.5 REST OF ASIA PACIFIC 173
9.6 LATIN AMERICA 176
9.6.1 BRAZIL 178
- 9.6.1.1 Rising government investments in research to propel market growth 178
9.6.2 MEXICO 180
- 9.6.2.1 Synthetic biology research advancements to drive market growth 180
9.6.3 REST OF LATIN AMERICA 182
9.6.4 MIDDLE EAST & AFRICA 184
- 9.6.4.1 Growing pharmaceutical & biotechnology industries and increasing R&D activities to drive market growth 184
10 COMPETITIVE LANDSCAPE 187
10.1 INTRODUCTION 187
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 188
10.3 REVENUE SHARE ANALYSIS 189
10.4 MARKET SHARE ANALYSIS 189
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 191
10.5.1 STARS 192
10.5.2 EMERGING LEADERS 192
10.5.3 PERVASIVE PLAYERS 193
10.5.4 PARTICIPANTS 193
10.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 193
10.6.1 PRODUCT FOOTPRINT OF COMPANIES (25 COMPANIES) 193
10.6.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES) 194
10.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES 196
10.7.1 PROGRESSIVE COMPANIES 197
10.7.2 STARTING BLOCKS 197
10.7.3 RESPONSIVE COMPANIES 197
10.7.4 DYNAMIC COMPANIES 197
10.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 197
10.9 COMPETITIVE SCENARIO AND TRENDS 199
10.9.1 PRODUCT LAUNCHES 199
10.9.2 DEALS 200
10.9.3 OTHER DEVELOPMENTS 200
11 COMPANY PROFILES 201
11.1 KEY PLAYERS 201
11.1.1 THERMO FISHER SCIENTIFIC 201
11.1.2 MERCK KGAA 205
11.1.3 GENSCRIPT BIOTECH CORPORATION 209
11.1.4 BACHEM HOLDING AG 213
11.1.5 KANEKA CORPORATION 217
11.1.6 BIOTAGE AB 222
11.1.7 SYNGENE INTERNATIONAL LIMITED 225
11.1.8 MESA LABORATORIES, INC 227
11.1.9 CEM CORPORATION 231
11.1.10 PROTEOGENIX 234
11.1.11 BIO-SYNTHESIS INC 236
11.1.12 DALTON PHARMA SERVICES 238
11.1.13 AAPPTEC 239
11.1.14 VIVITIDE 242
11.1.15 ANYGEN CO., LTD 243
11.2 OTHER PLAYERS 244
11.2.1 CSBIO 244
11.2.2 ADVANCED CHEMTECH 245
11.2.3 LUXEMBOURG BIO TECHNOLOGIES LTD 245
11.2.4 JPT PEPTIDE TECHNOLOGIES GMBH 246
11.2.5 AMBIOPHARM INC 246
11.2.6 AURIGENE PHARMACEUTICAL SERVICES LTD 247
11.2.7 CORDENPHARMA INTERNATIONAL 247
11.2.8 CHEMPEP INC 248
11.2.9 CPC SCIENTIFIC INC 249
11.2.10 PUROLITE PVT. LTD 249
12 APPENDIX 250
12.1 DISCUSSION GUIDE 250
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 254
12.3 CUSTOMIZATION OPTIONS 256
12.4 RELATED REPORTS 256
12.5 AUTHOR DETAILS 257